Rheumatology in Colorado Springs, CO
13 verified rheumatology doctors in Colorado Springs.
Rheumatologists treat autoimmune and inflammatory conditions affecting the joints, muscles, and connective tissue.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Michael Baker, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Melissa Hocate, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Martha Dambrosio Md, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Michael Sayers, DO
Rheumatology
CMS Open Payments· $270.19 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$270.19
Total received
18
Transactions
6
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 61th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Michael Sayers do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Megan Macneil, MD
Rheumatology
CMS Open Payments· $842.73 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$842.73
Total received
50
Transactions
11
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 71th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Megan Macneil do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Patrice Leonard, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Robert Kowalewski, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Dan Cristescu, MD
Rheumatology
CMS Open Payments· $716.26 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$716.26
Total received
55
Transactions
7
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 69th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Dan Cristescu do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Christopher Chong, MD
Rheumatology
CMS Open Payments· $1,642 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$1,642
Total received
105
Transactions
19
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 77th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Christopher Chong do not imply any wrongdoing. Many are meals, education, or research support.
Dr. David Theis, MD
Rheumatology
CMS Open Payments· $6,407 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$6,407
Total received
152
Transactions
20
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 89th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to David Theis do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Swosti Roka Magar, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Christopher Inserra, MD
Rheumatology
CMS Open Payments· $182.76 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$182.76
Total received
7
Transactions
7
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 58th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Christopher Inserra do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Jimmie White, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.